189
Views
16
CrossRef citations to date
0
Altmetric
Review

PEGylated bioactive molecules in biodegradable polymer microparticles

, PhD, , PhD, , PhD & , PhD
Pages 1427-1436 | Published online: 29 Aug 2007

Bibliography

  • CHIU Y, SOBEL S: Protein and peptide drug delivery systems: a regulatory viewpoint. In: Therapeutic Peptides and Proteins: Formulation, Delivery, and Targeting. Marshak D, Liu D (Eds), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA (1989):187-193.
  • TICE T: Delivering with depot formulations. Drug Delivery Technol. (2004) 4:44-47.
  • BECK L, COWSAR D, LEWIS D et al.: A new long-acting injectable microcapsule system for the administration of progesterone. Fertil. Steril. (1979) 31:545-551.
  • LEWIS D: Controlled release of bioactive agents from lactide/glycolide polymers. In: Biodegradable Polymers as Drug Delivery Systems. Chasin M, Langer R (Eds), Marcel Dekker, Inc., Baltimore, Cambridge, USA (2001):1-41.
  • BECK L, POPE V, FLOWERS C et al.: Poly(D,L-Lactide-co-glycolide)/norethisterone microcapsules: an injectable biodegradable contraceptive. Biol. Reprod. (1983) 28:186-195.
  • KEMP S, FIELDER P, ATTIE K et al.: Pharmacokinetic and pharmacodynamic characteristics of a long-acting growth hormone (GH) preparation (Nutropin Depot) in GH-Deficient children. J. Clin. Endocrinol. Metab. (2004) 89:3234-3240.
  • CROTTS G, SAH H, PARK T: Adsorption determines in vitro protein release rate from biodegradable microspheres: quantitative analysis of surface area during degradation. J. Control. Release (1997) 47:101-111.
  • TSAI T, MEHTA R, DELUCA P: Adsorption of peptides to poly(D,L-lactide-co-glycolide). 1. Effect of physical factors on the adsorption. Int. J. Pharm. (1996) 127:31-42.
  • DE JONG S, ARIAS E, RIJKERS D, VAN NOSTRUM C, KETTENES-VAN DEN BOSCH J, HENNINK W: New insights into the hydrolytic degradation of poly(lactic acid): participation of the alcohol terminus. Polymer (2001) 42:2795-2802.
  • BRUNNER A, MADER K, GOPFERICH A: pH and osmotic pressure inside biodegradable microspheres during erosion. Pharm. Res. (1999) 16:847-853.
  • DING A, SCHWENDEMAN S: Determination of water-soluble acid distribution in poly(lactide-co-glycolide). J. Pharm. Sci. (2004) 93:322-331.
  • LAI M, HAGEMAN M, SCHOWEN R, BORCHARDT R, LAIRD B, TOPP E: Chemical stability of peptides in polymers. 2. Discriminating between solvent and plasticizing effects of water on peptide deamidation in poly(vinylpyrrolidone). J. Pharm. Sci. (1999) 88:1081-1089.
  • KROGMEIER S, REDDY S, VANDER VELDE D et al.: Deamidation of model b-turn cyclic peptides in the solid state. J. Pharm. Sci. (2005) 94:2616-2631.
  • JOSHI A, SAWAI M, KEARNEY W, KIRSCH L: Studies on the mechanism of aspartic acid cleavage and glutamine deamidation in the acidic degradation of glucagon. J. Pharm. Sci. (2005) 94:1912-1927.
  • IBRAHIM M, ISMAIL A, FETOUH M, GOPFERICH A: Stability of insulin during the erosion of poly(lactic acid) and poly(lactic-co-glycolic acid) microspheres. J. Control. Release (2005) 106:241-252.
  • DE BONT R, VAN LAREBEKE N: Endogenous DNA damage in humans: a review of quantitative data. Mutagenesis (2004) 19:169-185.
  • VAN DE WEERT M, HENNINK W, JISKOOT W: Protein instability in poly(lactic-co-glycolic acid) microparticles. Pharm. Res. (2000) 17:1159-1167.
  • JIANG W, SCHWENDEMAN S: Stabilization and controlled release of bovine serum albumin encapsulated in poly(D,L-lactide) and poly(ethylene glycol) microsphere blends. Pharm. Res. (2001) 18:878-885.
  • SHAO P, BAILEY L: Stabilization of pH-induced degradation of porcine insulin in biodegradable polyester microspheres. Pharm. Develop. Technol. (1999) 4:633-642.
  • ZHU G, MALLERY S, SCHWENDEMAN S: Stabilization of proteins encapsulated in injectable poly(lactide-co-glycolide). Nat. Biotechnol. (2000) 18:52-57.
  • LUCKE A, KIERMAIER J, GOPFERICH A: Peptide acylation by poly(a-hydroxy esters). Pharm. Res. (2002) 19:175-181.
  • NA D, YOUN Y, LEE S et al.: Monitoring of peptide acylation inside degrading PLGA microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry. J. Control. Release (2003) 92:291-299.
  • MURTY S, GOODMAN J, THANOO B, DELUCA P: Identification of chemically modified peptide from poly(D,L-lactide-co-glycolide) microspheres under in vitro release conditions. AAPS Pharm. Sci. Tech. (2003) 4:E49.
  • CALICETI P, VERONESE F: Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. (2003) 55:1261-1277.
  • KOZLOWSKI A, CHARLES S, HARRIS J: Development of PEGylated interferons for the treatment of chronic hepatitis C. BioDrugs (2001) 15:419-429.
  • HINDS K, KIM S: Effects of PEG conjugation on insulin properties. Adv. Drug Deliv. Rev. (2002) 54:505-530.
  • ROBERTS M, BENTLEY M, HARRIS J: Chemistry for peptide and protein PEGylation. Adv. Drug Deliv. Rev. (2002) 54:459-476.
  • GREENWALD R, CHOE Y, MCGUIRE J, CONOVER C: Effective drug delivery by PEGylated drug conjugates. Adv. Drug Deliv. Rev. (2003) 55:217-250.
  • DELGADO C, FRANCIS GE, FISHER D: The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carrier Syst. (1992) 9:249-304.
  • DIWAN M, PARK T: PEGylation enhances protein stability during encapsulation in PLGA microspheres. J. Control. Release (2001) 73:233-244.
  • DIWAN M, PARK T: Stabilization of recombinant interferon-a by PEGylation for encapsulation in PLGA microspheres. Int. J. Pharm. (2003) 252:111-122.
  • KIM T, LEE H, PARK T: PEGylated recombinant human epidermal growth factor (rhEGF) for sustained release from biodegradable PLGA microspheres. Biomaterials (2002) 23:2311-2317.
  • AL-AZZAM W, PASTRANA E, KING B, MENDEZ J, GRIEBENOW K: Effect of the covalent modification of horseradish peroxidase with poly(ethylene glycol) on the activity and stability upon encapsulation in polyester microspheres. J. Pharm. Sci. (2005) 94:1808-1819.
  • CASTELLANOS I, AL-AZZAM W, GRIEBENOW K: Effect of the covalent modification with poly(ethylene glycol) on a-chymotrypsin stability upon encapsulation in poly(lactic-co-glycolic) microspheres. J. Pharm. Sci. (2005) 94:327-340.
  • CAMPBELL K, HINDS K, HOLLAND K, LEWIS D: PEG-insulin conjugates for optimal microsphere formulations. Proc. Intern. Symp. Control. Rel. Bioact. Mater. (2004) 31:484.
  • HINDS K, CAMPBELL K, HOLLAND K, LEWIS D, PICHE C, SCHMIDT P: PEGylated insulin in PLGA microparticles. In vivo and in vitro analysis. J. Control. Release (2005) 104:447-460.
  • KELLNER K, TESSMAR J, MILZ S et al.: PEGylation does not impair insulin efficacy in three-dimensional cartilage culture: an investigation toward biomimetic polymers. Tissue Eng. (2004) 10:429-440.
  • COOK G: Evaluation of PLGA microspheres for intraocular sustained delivery of pegaptanib. Proc. Intern. Symp. Control. Rel. Bioact. Mater. (2006) 33:56.
  • INADA Y, NISHIMURA H, TAKAHASHI K, YOSHIMOTO T, SAHA AR, SAITO Y: Ester synthesis catalyzed by polyethylene glycol-modified lipase in benzene. Biochem. Biophys. Res. Commun. (1984) 122:845-850.
  • MARSAC Y, CRAMER J, OLSCHEWSKI D, ALEXANDROV K, BECKER CF: Site-specific attachment of polyethylene glycol-like oligomers to proteins and peptides. Bioconj. Chem. (2006) 17:1492-1498.
  • WIRTH P, SOUPPE J, TRITSCH D, BIELLMANN J: Chemical modification of horseradish peroxidase with ethanal-methoxypolyethylene glycol: solubility in organic solvents, activity, and properties. Bioorg. Chem. (1991) 19:133-142.
  • MURTY S, THANOO B, WEI Q, DELUCA P: Impurity formation studies with peptide-loaded polymeric microspheres Part II. In vitro evaluation. Int. J. Pharm. (2005) 297:62-72.
  • MURTY S, WEI Q, THANOO B, DELUCA P: Impurity formation studies with peptide-loaded polymeric microspheres Part I. In vivo evaluation. Int. J. Pharm. (2005) 297:50-61.
  • NA D, DELUCA P: PEGylation of Octreotide. I. Separation of positional isomers and stability against acylation by poly(D,L-lactide-co-glycolide). Pharm. Res. (2005) 22:736-742.
  • NA D, LEE K, DELUCA P: PEGylation of Octreotide. II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics. Pharm. Res. (2005) 22:743-749.
  • NA D, MURTY S, LEE K, THANOO B, DELUCA P: Preparation and stability of poly(ethylene glycol) (PEG)ylated octreotide for application to microsphere delivery. AAPS Pharm. Sci. Tech. (2003) 4:E72.
  • YEO Y, PARK K: Control of encapsulation efficiency and initial burst in polymeric microparticle systems. Arch. Pharm. Res. (2004) 27:1-12.
  • YAMAGUCHI Y, TAKENAGA M, KITAGAWA A, OGAWA Y, MIZUSHIMA Y, IGARASHI R: Insulin-loaded biodegradable PLGA microcapsules: Initial burst release controlled by hydrophilic additives. J. Control. Release (2002) 81:235-249.
  • FU K, HARRELL R, ZINSKI K et al.: A potential approach for decreasing the burst effect of protein from PLGA microspheres. J. Pharm. Sci. (2003) 92:1582-1591.
  • VERONESE F, MORPURGO M: Bioconjugation in pharmaceutical chemistry. Farmaco (1999) 54:497-516.
  • TSUBERY H, MIRONCHIK M, FRIDKIN M, SHECHTER Y: Prolonging the action of protein and peptide drugs by a novel approach of reversible polyethylene glycol modification. J. Biol. Chem. (2004) 279:38118-38124.
  • YOUN Y, NA D, LEE K: High-yield production of biologically active mono-PEGylated salmon calcitonin by site-specific PEGylation. J. Control. Release (2007) 117:371-379.
  • YEH MK: The stability of insulin in biodegradable microparticles based on blends of lactide polymers and polyethylene glycol. J. Microencapsul. (2000) 17:743-756.
  • HINDS K, KOH J, JOSS L, LIU F, BAUDYS M, KIM S: Synthesis and characterization of poly(ethylene glycol) – insulin conjugates. Bioconjug. Chem. (2000) 11:195-201.
  • THIEL K: Oligo oligarchy – the suprisingly small world of aptamers. Nat. Biotechnol (2004) 22:649-651.
  • TUCKER C, CHEN L, JUDKINS M, FARMER J, GILL S, DROLET D: Detection and plasma pharmacokinetics of an anti-vascular endothelial growth factor oligonucleotide-aptamer (NX1838) in Rhesus monkeys. J. Chromatogr. B. (1999) 732:203-212.
  • DROLET D, NELSON J, TUCKER C et al.: Pharmacokinetics and safety of an anti-vascular endothelial growth factor aptamer (NX1838) following injection into the vitreous humor of Rhesus monkeys. Pharm. Res. (2000) 17:1503-1510.
  • GRAGOUDAS E, ADAMIS A, CUNNINGHAM E, FEINSOD M, GUYER D: Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med. (2004) 351:2805-2816.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.